A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body
NCT03241264
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Fibrosis
Interventions
DRUG:
ND-L02-s0201
Sponsor
Bristol-Myers Squibb
Collaborators
[object Object]